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Protocol
AbstrAct
Introduction Since 2011, the Spanish Society of Family 
Medicine has recommended general practitioners (GPs) 
to ask their patients to stop taking antibiotics when they 
suspect a viral infection. However, this practice is seldom 
used because uncertainty about diagnosis, and fear of 
consequences of discontinuing antibiotic therapy, as well 
as perceived pressure to continue prescribing antibiotics 
and potential conflict with patients are more of a concern 
for GPs than antibiotic resistance. The main objective 
of this study is to determine whether discontinuation 
of antibiotic therapy when a GP no longer considers it 
necessary has any impact on the number of days with 
severe symptoms.
Methods and analysis This is a multicentre, open-
label, randomised controlled clinical trial. The study 
was conducted in 10 primary care centres in Spain. 
We included patients from 18 to 75 years of age with 
uncomplicated acute respiratory tract infections—
acute rhinosinusitis, acute sore throat, influenza or 
acute bronchitis—who had previously taken any dose 
of antibiotic for <3 days, which physicians no longer 
considered necessary. The patients were randomly 
assigned to the usual strategy of continuing antibiotic 
treatment or to discontinuing antibiotic therapy. A sample 
size of 240 patients per group was calculated on the basis 
of a reduction of 1 day in the duration of severe symptoms 
being a clinically relevant outcome. The primary outcome 
was the duration of severe symptoms, that is, symptoms 
scored 5 or 6 by means of validated symptom diaries. 
Secondary outcomes included antibiotics taken, adverse 
events, patient satisfaction and complications within the 
first 3 months.
Ethics and dissemination The study was approved 
by the Ethical Board of Fundació Jordi Gol i Gurina 
(reference number: 16/093). The findings of this trial will 
bedisseminated through research conferences and peer-
reviewed journals.
Trial registration number NCT02900820; pre-results.
Background
Acute respiratory tract infections (RTIs) 
are among the most common reasons for a 
healthcare encounter in Western countries, 
accounting for about 15% of all visits.1 
Most episodes are caused by viruses, and in 
otherwise healthy adults these infections are 
typically self-limiting and do not require a visit 
to a physician or a prescription medication. 
Nevertheless, many patients with uncompli-
cated, self-limited RTIs seek care in primary 
care offices. A recent study found that 72% 
of primary care visits due to an acute respira-
tory tract infection did not seem to require 
an office visit,2 which subsequently increases 
Strengths and limitations of this study
 ► The open design of this study will allow us to study 
the perceptions of patients in a situation similar 
to that of usual practice. Apart from its pragmatic 
design, our study will be the first trial to assess 
if discontinuation of antibiotic therapy when a 
general practitioner no longer considers it necessary 
has any impact on the number of days with severe 
symptoms.
 ► Some patients might not complete the symptom 
diaries. However, strategies to improve diary return 
rates will be implemented and reminder telephone 
calls will be made to non-respondents.
 ► The open nature of the study may cause a placebo 
effect favouring antibiotics. However, this effect will 
be minimised by the similar structured information 
all patients will receive about the self-limiting nature 
of respiratory tract infections and advice about the 
use of non-antibiotic medications.
 ► This trial might be underpowered for the detection 
of differences between the two groups in terms of 
adverse events and complications within the first 
3 months, since these outcomes are considered 
secondary end points in this study.
 ► Another possible limitation of this study is the fact 
that microbiological studies will not be taken into 
account. In primary care, the response to treatment 
in respiratory tract infections is mainly judged by 
clinical rather than microbiological criteria.
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healthcare costs and often leads to inappropriate anti-
biotic prescription.3 4 Very importantly, inappropriate 
overuse of antibiotic medications can be very detrimental 
and may lead to antibiotic resistance,5 6 which has a 
tremendous impact on the economy,7 and patients often 
experience adverse effects such as diarrhoea, thrush, 
nausea, urticaria and rash, which give rise to further 
office visits and time off work. Despite being uncommon, 
patients might also experience serious complications 
such as anaphylaxis and Clostridium difficile infection.8 In 
addition, medicalisation of a self-limited condition makes 
it more likely for patients to visit a healthcare provider the 
next time they have a similar episode.9
General practitioners (GPs) have generally been told 
to continue an antibiotic regimen once the patient has 
initiated it in order to prevent the patient from acquiring 
resistant organisms. However, this dogma of completing 
an antibiotic regimen once initiated might not be associ-
ated with less antimicrobial resistance. Some studies have 
shown that short-course regimens can be as effective as 
longer courses of therapy, resulting in less emergence 
of antibiotic resistance, which is consistent with what we 
know about natural selection, the driver of antibiotic 
resistance.10–12 The use of shorter therapies, defined as 
the taking of an antibiotic for 5 days or less, is commonly 
used for uncomplicated urinary tract infections. Short 
course regimens—from 3 to 5 days—have also shown 
to be as effective as longer therapies in community-ac-
quired pneumonia, acute bacterial sinusitis and acute 
exacerbations of chronic obstructive pulmonary disease 
but are seldom used by GPs.13 When it comes to pneu-
monia, despite the efforts of infectious committees and 
guidelines developed by different societies, the duration 
of antibiotic use is still a major issue for which there is a 
lack of adherence both in primary and secondary care 
worldwide.14
This often-heard statement of completing an antibi-
otic course once initiated and the perceived need to 
treat beyond resolution of symptoms is usually driven by 
a desire to prevent worse outcomes and relapses. Giving 
the right antibiotic at an adequate dose, along with good 
compliance with the daily regimen by the patient (ie, 
taking the correct dose at the appropriate intervals), has 
been said to be the most important strategy for treatment 
success in bacterial infections.15 However, GPs very often 
see patients with suspected viral infections of the upper 
and lower airways, for which antibiotic treatment makes 
little or no difference in terms of clinical outcomes and, 
conversely, can cause some side effects and might also 
prompt the acquisition of resistant organisms.16
Since 2011, the Spanish Society of Family Medicine has 
recommended GPs to ask their patients to stop taking 
antibiotics given by other clinicians when they suspect 
a viral infection.17 Despite this recommendation, this 
strategy is seldom used in routine clinical practice. GPs 
are reluctant and feel that it is unsafe to discontinue an 
antibiotic once the patient has already started it, mainly 
due to the ambiguity about the appropriateness of 
discontinuing medication felt by GPs, and in part because 
the clinical guidelines do not encourage discontinu-
ation of medication, as they offer GPs a weak rationale 
for discontinuation.18 In addition, some studies have 
also shown that other issues such as uncertainty about 
diagnosis, ease of follow-up and fear of consequences of 
non-prescribing as well as perceived pressure to prescribe 
and potential conflict with patients which might lead to 
consequences for the future doctor–patient relationship 
are more of a concern for GPs continuing to prescribe 
antibiotics than antibiotic resistance.19 When it comes to 
acute infections, GPs might feel uncomfortable to discon-
tinue antibiotic therapy from a patient who subsequently 
deteriorates, especially if the patient needs to be admitted 
to hospital.20 There is limited evidence about the effi-
cacy and safety of continuing an antibiotic regimen if 
not needed, but concomitantly, evidence as to whether 
discontinuing antibiotic therapy for these conditions is 
safe is lacking, and studies demonstrating the safety of 
this practice should be carried out.
Discontinuing an antibiotic regimen could be under-
taken in one of the following two situations:
1. Patients diagnosed with infectious diseases for which 
antibiotics—prescribed by other physicians—are not 
necessary, that is, an antibiotic course for suspected viral 
infections
According to WHO, 80% of the RTIs in the community 
have a viral origin. Most of these infections are self-lim-
iting, and recent systematic reviews have suggested that 
antibiotics only slightly modify the course of most of 
these infections. A recent systematic review suggested 
that antibiotics do not improve the duration of symp-
toms in patients with common cold compared with those 
receiving placebo.21 Antibiotics are associated with modest 
benefits in sore throat; they reduce soreness and fever, 
the duration of symptoms and the incidence of suppu-
rative and non-suppurative complications compared 
with placebo mainly in patients with infection caused by 
group A β-haemolytic streptococcus.22 This modest effect 
of antibiotics has also been observed in acute rhinosinus-
itis in which antibiotics can shorten the time to cure, but 
only five participants per 100 cure faster at any time point 
between 1 and 2 weeks if they receive antibiotics instead 
of placebo.23 In acute bronchitis, no difference has been 
shown between antibiotic and placebo groups in terms of 
the percentage of patients described as achieving clinical 
improvement at follow-up.24 However, the participants in 
all these clinical trials had a significantly greater risk of 
adverse effects with antibiotics than with placebo.25
Despite the low percentage of bacterial infections, anti-
biotic prescription is very high in these infectious diseases, 
with over 60% of adults presenting with acute rhinosi-
nusitis, acute bronchitis and acute sore throat receiving 
an antibiotic in Spain.26 Antibiotic prescription in our 
country has increased over the last years and Spain now 
constitutes one of the leading countries in the world when 
it comes to the percentage of antibiotics prescribed.27 28 
This unnecessary antibiotic prescription in RTIs has also 
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been seen in other affluent countries; in addition, these 
antibiotics are increasingly broad-spectrum antimicrobial 
agents.29 30 Even in Holland, the country with the lowest 
antibiotic consumption in Europe, 46% of the antibiotics 
prescribed for RTIs are not needed while in only 4% of 
the situations in which antibiotics are not prescribed they 
should have been recommended according to the Dutch 
guidelines.31 This unnecessary antibiotic prescription 
might mainly be explained by uncertainty in the diagnosis 
and by GPs’ perceptions regarding patient expectations 
for a prescription.32 33 Data from the Genomics to combat 
resistance against antibiotics in community-acquired 
lower respiratory tract infections in Europe study clearly 
show that antibiotics are expected by 45% of the patients 
with lower RTIs.34
2. Patients who have taken several doses of an anti-
biotic not prescribed by a health professional for an 
infectious disease for which antibiotics are not neces-
sary, that is, from leftovers found in the household or 
an antibiotic bought without prescription at the phar-
macy.
The sale of antibiotics and other antimicrobial medi-
cines without a prescription remains widespread, with 
many countries lacking standard treatment guidelines, 
thereby increasing the potential for overuse of antimicro-
bial medicines by the public and medical professionals.35 
This practice is common outside Northern Europe and 
North America. The percentage of non-prescription 
access to antimicrobials is often underestimated and also 
depends on the methodology used for making estima-
tions. In 2016, the European Commission published a 
questionnaire-based study (Eurobarometer), which was 
carried out in 28 European countries, including 1053 
respondents in Spain. This study described that 6% of 
users reported having obtained antibiotics in the previous 
year without a prescription or stated that they had used 
the leftovers from a previous course.36 However, when 
more reliable methods are used to know how many indi-
viduals obtain antibiotics from sources other than their 
GPs, these percentages clearly increase.37 Self-medication 
with antimicrobials is also widespread, occurring among 
the population in the same countries in which over-the-
counter sales are available.38
STudy aimS
The main objective of the present trial is to know if the 
discontinuation of antibiotic therapy when a GP no longer 
considers it necessary has any impact on the number of 
days with severe symptoms.
Secondary objectives:
1. Assessment of the incidence of adverse effects.
2. Assessment of antibiotic consumption.
3. Assessment of the satisfaction with healthcare and 
belief in the effectiveness of antibiotics by the 
patients included.
4. Assessment of the number of complications 
observed within the first 3 months.
meThodS and analySiS
Study design
This was a multicentre, open-label, randomised controlled 
clinical trial comparing two therapeutic strategies for 
uncomplicated acute RTIs. Patients were randomly 
assigned to either the usual strategy of continuing anti-
biotic treatment or discontinuing antibiotic therapy. The 
randomisation was stratified by condition of interest—
acute sore throat, rhinosinusitis (including common cold), 
acute bronchitis and influenza. GPs randomised patients 
using a centralised electronic online platform. An open-
label study has been designed taking into account the 
type of the two strategies used and considering that an 
effect on GPs’ and patients’ beliefs is expected. Neither 
patients nor health professionals will be blinded.
eligibility criteria
Any patient from 18 to 75 years of age attending the GP 
consultation with an uncomplicated RTI who had previ-
ously taken any dose of antibiotic for <3 days due to either 
of the two following clinical scenarios and accepted to 
participate in the clinical trial were included:
 ► Patients diagnosed with clinical conditions for which 
antibiotics prescribed by other health professionals 
are not necessary.
 ► Patients who have taken several doses of an antibiotic 
(from leftovers found in the household or obtained 
at the pharmacy without a medical prescription) for 
a clinical condition for which an antibiotic is not 
necessary.
exclusion criteria
 ► Subjects under 18 or over 75 years of age.
 ► Confirmed bacterial infection.
 ► Patients requiring hospital admission.
 ► Severe impairment of clinical signs of infection 
(impairment of consciousness, respiratory rate >30 
respirations per minute, heart rate >125 beats per 
minute, systolic blood pressure <90 mm Hg, diastolic 
blood pressure <60 mm Hg, temperature >40°C, 
oxygen saturation <92%).
 ► Problems to comply with treatment at home, such 
as sociopathy or psychiatric problems or drug or 
alcohol addiction.
 ► Lack of tolerance to oral treatment, such as the 
presence of nausea and vomiting, gastrectomy, 
postsurgery and/or diarrhoea.
 ► Significant comorbidity including severe renal 
failure, hepatic cirrhosis, severe heart failure, 
immunosuppression—chronic HIV infection, 
transplantation, neutropaenia or patients receiving 
immunosuppressive drugs or corticosteroids.
 ► Terminal disease, defined as a life expectancy <12 
months.
 ► Patients admitted to a long-term residence.
 ► Patients who state that they are unable to see their 
doctor at the practice office.
 ► Refusal to participate in the study.
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outcome measures
The primary outcome measure was the duration of severe 
symptoms. Each symptom was scored using a six-point 
Likert scale and symptoms scoring 5 or 6 was considered 
as severe. We included common symptoms such as feeling 
of fever, discomfort or general malaise, cough, difficulty 
in sleeping and changes in everyday life in all patients, and 
specific symptoms according to the condition (table 1).39
Secondary end points
 ► Adverse events in the two study groups.
 ► Antibiotic consumption. This information was 
collected in the symptom diaries and also by the 
pharmacy units of the different healthcare systems.
 ► Patient satisfaction with healthcare by means of a 
questionnaire with a Likert scale.
 ► Patient belief in the effectiveness of antibiotics by 
means of a questionnaire with a Likert scale.
 ► Complications related to the RTIs were registered 
during the first 3 months after randomisation. As in 
the recent study by Gulliford et al, we considered the 
cases of pneumonia, empyema, peritonsillar abscess, 
mastoiditis, otitis media, bacterial meningitis and 
intracranial abscess.40 These complications were 
prospectively recorded by the GPs by means of 
a standardised questionnaire and were reported 
within a maximum of 48 hours to the study clinical 
coordinator, who reported to the Safety and Data 
Monitoring Committee, which assessed the safety of 
the two strategies.
Sample size calculation
Excellence guidelines for the treatment of RTIs included 
estimates of average duration of the illness (before and 
after seeing a doctor) of 1 week for acute sore throat, one 
and a half weeks for rhinosinusitis, including common 
cold and 3 weeks for acute cough or bronchitis.39 In a 
recent study on the effectiveness of delayed prescribing 
strategies carried out in Spain, the mean duration of 
severe symptoms in uncomplicated acute RTIs including 
acute sore throat, rhinosinusitis and acute bronchitis, 
among patients not treated with antibiotics was 4.7 days 
(SD of 3.6).39 Considering a reduction of 1 day in the dura-
tion of severe symptoms as a clinically relevant outcome, 
with a bilateral approximation, a sample of 240 patients 
per group was able to detect this difference with an alpha 
error of 5% and a power of 80% (beta=0.2), considering 
15% of losses (based on the percentage of patients who 
did not return symptom diaries in a previous study).39 In 
terms of the number of investigators to be included in this 
clinical trial, we anticipated that over a 2-year period each 
GP would include 32 patients. Thus, we are planning to 
invite 15 GPs from 10 different healthcare centres.
data collection and ascertainment of visits
The patients were randomised to one of the two treatment 
strategies. Baseline data were collected in the clinic by the 
physician or with the help of the nursing staff. To stan-
dardise data collection, all of the participating healthcare 
professionals were trained by the coordinating centre. 
Only experienced GPs (those who have worked for 15–25 
years) and those who feel comfortable with the design of 
the study participated in the study. This was achieved by 
the administration of a questionnaire with clinical ques-
tions, recommendations of local guidelines and vignettes 
to check if they were confident and comfortable with 
the strategy of stopping an already commenced antibi-
otic course. The patients received information on the 
study and, if they were interested in participating, they 
provided with an informed consent form to read and 
sign. A maximum length of 15–20 min was expected for 
the interview and the introduction of the data. The study 
scheme and the visit programme were explained to the 
patient (table 2). GPs filled out a screening log with all 
the patients who met all the inclusion criteria and none 
of the exclusion criteria regardless of whether the patients 
Table 1 Symptom diary. For each symptom choose the 
degree of affectation in the last 24 hours, according to the 
following Table of Codes.
Code Explanation
0 Normal/does not hurt
1 Affectation is insignificant/mild pain
2 Mild or slightly significant affectation/moderate pain
3 Moderately significant affectation/considerable pain
4 Significant affectation/intense pain
5 Highly significant affectation/very intense pain
6 Maximum affectation/unbearable pain
Acute sore throat. The following symptoms were recorded daily: 
feeling of fever, headache, general discomfort or malaise, cough, 
sore throat, difficulty swallowing (solids or liquids), runny nose, ear 
pain, diarrhoea, nausea, vomiting, difficulty sleeping and difficulty 
in carrying out daily life activities. Each symptom was scored 
following a 0–6 scale.
Rhinosinusitis. The following symptoms were recorded daily: 
feeling of fever, general discomfort or malaise, headache, sudden 
pain in the face, pain in the face on touching, runny nose, nasal 
mucus colour, cough, sore throat, expectoration or phlegm (mucus 
when coughing), diarrhoea, nausea, vomiting, difficulty sleeping 
and difficulty in carrying out daily life activities. Each symptom 
(save for nasal mucus colour) was scored from 0 to 6. In the case 
of the presence of nasal mucus colour, the colour was assessed: 
transparent (T), light yellow clear (Y), green (V) or other (O).
Acute bronchitis. The following symptoms were recorded 
daily: feeling of fever, general discomfort or malaise, cough, 
expectoration or phlegm (mucus when coughing), shortness of 
breath (suffocation, fatigue), pain when breathing (chest pain), 
chest breathing sounds, diarrhoea, nausea, vomiting, difficulty 
sleeping and difficulty in carrying out daily life activities. Each 
symptom (save for expectoration or phlegm) was scored from 
0 to 6. In the case of expectoration or phlegm, the colour was 
assessed: transparent (T), light yellow clear (Y), green (V) or other 
(O).
Influenza. The following symptoms were recorded daily: feeling of 
fever, runny nose, headache, general discomfort or malaise, cough, 
muscle pain, sore throat, sweat or chills, shortness of breath, 
weakness or fatigue, dizziness, diarrhoea, nausea or vomiting, 
difficulty sleeping and difficulty in carrying out daily life activities. 
Each symptom was scored from 0 to 6.
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consent to participate or not. This allowed us to evaluate 
the percentage of patients who accepted to participate in 
the trial and determined the reasons why they did not 
wish to participate if they refuse.
On the baseline visit, GPs collected information about 
the type of diagnoses, prior time elapsed with symptoms, 
number of days taking an antibiotic and type of antibiotic 
taken. Patients who made the decision to take an antibi-
otic by themselves (either purchased at the pharmacy or 
taken from leftovers stored at home) and were assigned 
to the usual strategy of continuing antibiotic treatment 
were provided with a medical prescription of the same 
antibiotic until completing the recommended therapy 
duration according to local guidelines, even if the antibi-
otic was not first-line treatment.
After randomisation, information on the strategy to 
which they have been allocated was given to the partic-
ipants, and they were informed as to the appropriate 
measures to take in case their condition worsened or 
there was no improvement. In addition, they were given a 
diary with a validated questionnaire of symptoms for each 
condition, which they had to complete while symptoms 
related to the respiratory condition were present. The 
degree of satisfaction or concern with different aspects 
of the therapy as well as the use of antibiotics was also 
recorded in this diary.
Patients were interviewed by telephone 2 or 3 days 
after their inclusion in the study. At this first follow-up 
visit, a worsening of the clinical situation of the patient 
was evaluated to determine whether antibiotic treatment 
was necessary among patients in the group assigned 
to discontinuation (first-line antibiotics were recom-
mended in this case) or whether the antibiotic regimen 
should be continued or changed to the first-line drug 
in patients in the group allocated to continuation. We 
provided the patients with the opportunity to ask ques-
tions and discuss any problems with diary completion. 
In addition, compliance and possible secondary effects 
of the treatment were evaluated. The second follow-up 
visit was scheduled at 14–28 days after inclusion and 
depended on the infection involved at patient recruit-
ment as established in the National Institute for Health 
and Care Excellence guidelines.41 On this visit, the 
clinical evolution of the signs and symptoms were evalu-
ated and the need to change or continue the antibiotic 
treatment, respectively, was determined in the case of 
worsening of the clinical manifestations. The symptom 
diaries were collected on this visit. Participants who did 
not return their diary were telephoned by the trial team 
as a reminder and to enquire whether they needed any 
assistance in returning their diary. Possible secondary 
effects of the treatment were also assessed. Patients were 
asked to revisit if symptoms continued or they presented 
recurrence of the infection. On the last follow-up 
visit, scheduled at day 90, recurrences, medical visits 
or hospital admissions due to the baseline infectious 
disease were reported.
data analysis procedure
The characteristics of the study population will be 
described using frequencies for categorical variables 
and mean and SD for quantitative variables. A bivariate 
analysis of the baseline data will be performed between 
patients returning and not returning symptoms diaries 
for assessing if the latter population differ from the 
patients included in the study analysis. To compare the 
two strategies studied, we will use the t test for contin-
uous variables. To compare the duration of symptoms 
across strategies, we will use the t test for continuous vari-
ables for each symptom, and a linear regression model 
per symptom, with symptom duration as the dependent 
variable, and both antibiotic consumption and symptom 
duration prior to the visit as the independent variables. 
The same approach will be made to compare the severity 
of symptoms between the two strategies, but the depen-
dent variable for each model will be symptom severity. 
The χ2 test will be used to compare antibiotic consump-
tion, satisfaction, percentage of adverse effects and the 
Table 2 Visit schedule during the clinical trial
Visit 1, day 0 Visit 2*, day 2–3
Visit 3, day 
14–28† Visit 4*, day 90
Medical history and physical examination x x
Informed consent form x
Randomisation x
Giving out of symptom diaries x
Evaluation of clinical evolution x x
Assessment of adverse events x x
Collection of symptom diaries x
Reporting of recurrences, medical visits or hospital 
admissions due to the baseline infection
x x x
*Phone call.
†Depending on the infection (14 days for influenza and sore throat; 28 days for acute bronchitis and acute rhinosinusitis). A further visit should 
be scheduled if symptoms persist on visit 3.
group.bmj.com on January 2, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
6 Llor C, et al. BMJ Open 2017;0:e015814. doi:10.1136/bmjopen-2016-015814
Open Access 
appearance of complications between the two groups. 
The level of significance will be 5% (α=0.05).
Criteria for withdrawals were evidence of protocol viola-
tion, withdrawal of informed consent or a serious adverse 
event, defined as any untoward medical circumstance 
that results in death, is life-threatening, requires inpa-
tient hospitalisation or prolongs existing hospitalisation, 
results in persistent or significant disability/incapacity or 
requires intervention to prevent permanent impairment 
or damage. Patients may choose to interrupt the medica-
tion at any time during the course of the study. However, 
they were followed in the same way as the other patients. 
Analyses will follow the intention-to-treat principle.
eThicS and diSSeminaTion
Each patient provided written consent to participate in 
the study after being informed in intelligible language for 
him/her on the nature, scope and possible consequences 
of the trial. After consent was submitted, the patients 
were randomised. Data confidentiality was ensured at all 
times, as stated in the researcher's commitment sheet, as 
will compliance with the current legislation regarding 
the protection of personal data. This was a clinical trial 
based on the outpatient setting, and neither patients nor 
researchers received any monetary compensation. From 
an ethical point of view, this is to certify that the objective 
of the study was relevant for primary care, the power of 
the study may be considered as reasonable, this was an 
original study, the risks which the participants may incur 
justify the study being carried out with a totally favour-
able benefit/risk quotient and we ensured the external 
validity of the study to the primary care reality, with clearly 
described inclusion and exclusion criteria. Vulnerable 
populations did not participate in this study.
The trial has been registered with the National Insti-
tutes of Health (NIH) trial registry (NCT02900820). This 
protocol was presented in the last Conference of the 
Spanish Society of Family Medicine held in La Coruña 
in June 2016. A range of dissemination activities are 
planned at national and international conferences. We 
will publish the final report in an open access peer-review 
journal (see online supplementary material). A summary 
of the findings will be sent to the participating practices 
on completion of the STOP Antibiotic Regimen (STOP-
AB) study.
diScuSSion
Overprescribing of antibiotics for RTIs is considerable 
in Western countries. The results of this study will be 
applicable to patients diagnosed with clinical conditions 
for which antibiotics are not or might not be necessary. 
Few GPs ask patients to discontinue antibiotic therapy 
because of fear of possible worsening of symptoms and the 
appearance of complications even in cases of suspected 
viral infections. Guidelines usually provide dominating 
triggers for prescribing and weak priming for discontin-
uation. In other situations, GPs do not wish to contradict 
the decision made by other doctors because it might look 
unfair. If the results of this study do not find any differ-
ence between the two groups, there will be no reason 
to continue an antibiotic regimen when a GP no longer 
considers it necessary. We believe that there is no risk—
and every advantage—in stopping a course of an antibiotic 
immediately after a bacterial infection has been excluded 
or is unlikely, as Gilbert recently suggested.16 The most 
obvious circumstances in which it is appropriate to stop 
antibiotics are when the antibiotics are initiated without 
certainty of what infection is being treated, if any treat-
able bacterial infection is present at all, and for infections 
that are almost always self-limiting, for example, episodes 
of acute bronchitis. Patient expectation often plays a role 
in the decision to start antibiotic treatment in these cases.
The impact of our trial is likely to be important since 
the evidence available in this field is still limited, and 
adequately designed and conducted clinical trials are 
warranted to clarify the efficacy and safety of discon-
tinuing antibiotic therapy in these cases. Similarly, the 
inclusion of most of the uncomplicated RTIs and the fact 
that only patients with <3 days of antibiotic therapy will 
be invited to participate will increase the validity of the 
results. These characteristics make this study innovative 
and relevant to this field.
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